How Should Multiple Models of Disinfection and Sterilization Equipment Be Grouped for Overseas Registration?

Disinfection and sterilization equipment manufacturers often ask how to group multiple models in overseas registration. First, determine whether the product is a medical device in the target country and its risk class. This defines the registration pathway and applicant. Most GHWP member countries allow structurally similar devices with the same intended use to be filed as a single registration unit, provided complete technical documentation is submitted, including performance verification, risk management, and clinical evaluation evidence. Existing data from NMPA, CE, or FDA can be reused, but must undergo localization—such as language translation, standard difference analysis, and adaptation of labels and instructions for use.

Common risks include improper grouping leading to deficiency letters, incomplete technical file coverage, unclear agent responsibilities, and lack of post-market maintenance. Manufacturers should establish a model matrix early, identify differences among models, define core technical files, and confirm grouping rules with the local agent. They must also maintain control over the certificate to ensure changes and renewals remain manageable. A platform-based strategy can reduce duplicate document preparation and deficiency risks across multiple countries.

For Chinese manufacturers, a prudent approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market data can be reused. Registration in a target market simultaneously affects technical files, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If the project is driven only by “which documents to submit,” deficiencies or rework often arise in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends treating this issue within a unified GHWP member country and multi-country access strategy, using one set of reusable core technical documents to support local adaptation across markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Issues

Disinfection and sterilization equipment is widely used in hospitals, laboratories, and industrial settings. Product categories include autoclaves (steam sterilizers), low-temperature hydrogen peroxide plasma sterilizers, ethylene oxide sterilizers, and ultraviolet disinfection devices. Manufacturers often create multiple models within the same product line, differing in chamber volume, control system, or installation method.

When planning to export these models, the practical question is whether they can be included in a single registration application. If they must be filed separately, costs and timelines multiply; if incorrectly combined, approval may be denied or post-market risks may arise. Understanding each target country's registration unit definition is the first step.

Multi-model grouping is not a one-size-fits-all concept. Different countries define registration units differently—for example, device groups under EU MDR, product codes and submission types under FDA, and registration units in GHWP member countries. Even within the same series, difference in intended use or key technical characteristics may require separate registration units.

Registration Determination Logic

First, confirm whether the product is classified as a medical device in the target country and identify its specific risk class. Disinfection and sterilization equipment typically falls into Class II or III, and may require notified body review or clinical trials depending on classification rules.

Second, determine the registration pathway and applicant. Most countries require a local representative or authorized agent, and the application is usually submitted by the manufacturer or the local agent. For multi-country registration, also consider specific technical file format requirements of each national regulatory authority.

Third, assess whether existing NMPA, CE, FDA, or other approved data can be reused. If the product is already registered domestically in China, NMPA registration files often contain product technical requirements and test reports that can serve as base documents.

Finally, identify localization requirements—translate instructions for use into local languages, adjust labels and cautions, conduct standard difference analysis, and complete clinical evaluation or performance verification to satisfy local requirements. For GHWP member countries, Southeast Asia, the Middle East, and Latin America, MDSAP or ISO 13485 certificates can help reduce audit duplication.

Technical Documentation and Evidence

Multi-model grouping documentation should be organized around a “core model.” Prepare a complete product description covering model naming conventions, structural differences, key performance parameters, and intended use.

Performance verification data should cover common characteristics across all models; additional verification may be needed for models with specific differences. Risk management should follow ISO 14971 and consider model-specific risks. If sterilization effectiveness or biocompatibility is involved, test reports must address the differences.

Clinical evaluation or clinical evidence is also important. For high-risk or new intended uses, literature data or clinical study summaries may be required. Labels and instructions for use must be localized, listing warnings, contraindications, and accessory lists per target country regulations.

Quality system certificates such as ISO 13485 and MDSAP are the foundation of international registration. Provide documents covering design and production processes, supplier management, and post-market surveillance.

For each registration unit, prepare the following core documents:

• Registration application form and authorization letter
• Model list and difference comparison table
• Technical file (including performance verification reports)
• Risk management documentation
• Clinical evaluation or exemption justification
• Labels and instructions for use
• Quality system certificate
• Local agent agreement and authorization

If these documents are submitted to multiple countries, establish a modular technical document library, adding country-specific difference documents to the core files.

Common Mistakes

Mistake 1: Forcing all models into a single registration unit, ignoring differences in intended use or key technical characteristics, leading to review questions.

Mistake 2: Omitting model difference analysis and submitting only one or two models' data, leaving reviewers unable to confirm coverage of other models.

Mistake 3: Overlooking local regulatory requirements—for example, some countries require independent test reports for each model or have specific standards for sterilizers.

Mistake 4: Relying on outdated regulatory conformity certificates—for example, submitting expired CE documentation to Southeast Asian countries.

Mistake 5: Failing to define the local agent's legal responsibilities, or not updating certificates when the agent changes, breaking the post-market complaint channel.

Mistake 6: Missing a post-market surveillance plan and failing to collect adverse events continuously, affecting certificate renewal and system updates.

Preparation Checklist

Build a “model matrix” listing chamber volume, voltage, frequency, controller, accessory differences, and assess whether models belong to the same registration unit.

Map the target country's medical device classification and registration pathway; draw a registration flowchart identifying applicant, agent requirements, and timeline.

Create a core document directory, archiving current technical files, test reports, and risk management reports by version, and mark reusable items.

Complete a local technical assessment—voltage/frequency compatibility, standards gap analysis, and translation of label warnings.

Plan the clinical evaluation strategy, such as using published literature, equivalence to a marketed device, or conducting clinical studies as needed.

Sign an authorization agreement with the local agent, clearly defining responsibilities for certificate custody, regulatory communication, and complaint handling.

Arrange post-market surveillance and periodic update procedures, ensuring that any changes are assessed for their impact on registration.

AIMEILI's Perspective

The most common misjudgment is applying domestic Chinese registration experience to overseas registration. In China, one production license often covers multiple models, but overseas, registration unit boundaries are stricter and tied to intended use and risk class. Being “in the same series” does not automatically allow grouping; blind grouping is a frequent cause of deficiency letters and delays.

We recommend conducting a “registrability assessment” at the beginning. Based on target country requirements, list all models, compare design and intended use item by item, identify core and differential models, and then decide grouping. This simple step prevents major rework.

Data from NMPA, CE, or FDA reviews can generally be reused, but formats and language must be localized. For instance, NMPA test reports need translation and reformatting; FDA Summary of Safety and Effectiveness may not match GHWP structure and must be converted to STED format.

The local agent is not a mere courier. Certificate control, change reporting, renewal applications, and even recall execution often rest with the agent. Define the agent's scope of service in the contract and retain final decision-making authority. If the agent changes, the certificate could become inaccessible, causing significant problems.

To reduce costs and improve efficiency in multi-country registration, the key is “modularization” and “parallelization.” We split core technical documents into common modules and country-specific modules, submit the same evidence to multiple countries simultaneously, and use GHWP harmonized documents and MDSAP certification to reduce redundant audits. With solid up-front model grouping and evidence chain construction, back-end corrections are greatly reduced.

Frequently Asked Questions

Must models with different specifications within the same family be registered separately?

Not necessarily. Specification differences—such as chamber volume—do not generally require separate registration units if intended use and technical principle remain unchanged, provided the technical file includes a difference analysis for each model. If differences affect sterilization parameters, energy output, or key performance, grouping should be assessed carefully, and additional verification data for differential models may be required.

Can CE registration documents be submitted directly to Middle East or Southeast Asian countries?

No, not directly. Most countries accept CE-based technical files as a foundation, but require conversion to local formats, such as STED or CSDT. Local agent information, language translation, and applicable standards differences must be added. If device voltage, plugs, or accessories differ locally, they must also be reflected in the documentation.

If one model in a grouped application is not approved, does it affect other models?

This depends on the review authority's decision. If rejection is due to high risk of the core model, the entire registration unit may be affected. If only a specific differential model is problematic, the authority may allow deleting that model or requesting supplemental data. To avoid cascading risk, clearly indicate the separability of models in the application and communicate with the review authority.

Published: 2026-08-28 | Updated: 2026-08-28